Gust J, Rawlings-Rhea SD, Wilson AL, Tulberg NM, Sherman AL, Seidel KD, Wu QV, Park JR, Gardner RA, Annesley CE (2023) GFAP and NfL increase during neurotoxicity from high baseline levels in pediatric CD19-CAR T-cell patients
Understanding your inflammatory markers, genetic predispositions in metabolic pathways, and current disease activity with your rheumatology team ensures any therapy aligns with your health goals and safety profile
Because of this, insurers often apply stricter prior authorization requirements for Zepbound, sometimes including step therapy (e.g., requiring failure of Wegovy first) or more extensive documentation of past treatment attempts
In early studies, patients lost 15% or more of their body fat within one year, and almost half the trial participants lost 20% of their body weight
The same caveat applies: the injectable format has robust clinical trial backing while the oral compounded version does not
Any therapies, consultations, or prescriptions are provided only following assessment by a licensed physician and where clinically appropriate
